<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336665">
  <stage>Registered</stage>
  <submitdate>15/03/2011</submitdate>
  <approvaldate>17/03/2011</approvaldate>
  <actrnumber>ACTRN12611000282987</actrnumber>
  <trial_identification>
    <studytitle>Emergency Department Anaphylaxis Trial II B - preliminary trial to confim pharmacokinetic profiles and study feasibility in patients with anaphylaxis treated with either intramuscular vs. intavenous adrenaline</studytitle>
    <scientifictitle>Randomisation of patients with anaphylaxis to either intramuscular vs. intravenous adrenaline - preliminary trial to confirm pharmacokinetic profiles and study feasibility of a composite endpoint</scientifictitle>
    <utrn />
    <trialacronym>EDAIIb</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anaphylaxis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparision of standard intramuscular adrenaline (0.01 mg/kg to a maximum of 0.5 mg - repeated once at 5-10 minutes as required) vs. intravenous infusion (1:100,000) titrated to effect (starting at 0.5 mls/kg/hr or 1.0 mls/kg/hr if hypotensive) in the initial management of patients with ananphylaxis</interventions>
    <comparator>Intramuscular adrenaline is deemed to be the control group.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary clinical endpoint will be resolution of main clinical features (defined by absence of the feature or improvement by at least 2 points on the ordinal severity scale) at 15 minutes.</outcome>
      <timepoint>15 minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The two groups will be compared for adverse effects such as myocardial ischaemia, myocardial infarction, hypertension and intracerebral haemorrhage. This will assessed via direct questioning, clinical assessment and continuous monitoring of ECG and Blood pressure</outcome>
      <timepoint>15 and 60 minutes</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Any acute onset (minutes-hours) illness with typical skin features (generalised hives, pruritus or flushing, swollen lips &amp;/or tongue), PLUS involvement of at least one other organ system (respiratory, cardiovascular, gastrointestinal)

-OR-

Any acute onset (minutes-hours) of hypotension or bronchospasm where anaphylaxis is considered possible, even if the typical skin features listed above are not present.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>14 years of age or less</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients presenting to Emergency Departments of participating hospitals. Sealed randomisation envelope held in ED.</concealment>
    <sequence>Allocations generated using a random number table with a 2:1 ratio (iv to im).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Craig Ellis</primarysponsorname>
    <primarysponsoraddress>Centre for Clinical Research in Emergency Medicine
West Australian Medical Research Institute
Royal Perth Hospital
Wellington Road
Perth 6001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Hawkes Bay Medical Research Foundation</fundingname>
      <fundingaddress>Hawke's Bay Medical Research Foundation Inc.
PO Box 596
Napier 4110
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Professor Simon Brown</sponsorname>
      <sponsoraddress>Centre for Clinical Research in Emergency Medicine
West Australian Medical Research Institute
Royal Perth Hospital
Wellington Road 
Perth 6001</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Anaphylaxis is a severe potentially life-threatening allergic reaction. The accepted management is intramuscular adrenaline. With intravenous adrenaline being a last resort therapy. The investigators believe that intravenous adrenaline given slowly as a dilute infusion is a better therapy, with more rapid onset (especially in patients with low blood pressure) with a similar side-effect profile to intramuscular adrenaline. This study is part of a wider PhD assessing this hypothesis and also the pharmacological behaviour of adrenaline.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Ethics Committee,
Royal Perth Hospital
Wellington Road
Perth 6001</ethicaddress>
      <ethicapprovaldate />
      <hrec>RPH EC 2010/085</hrec>
      <ethicsubmitdate>25/08/2010</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Craig Ellis</name>
      <address>c/o Emergency Department
Hawkes Bay Regional Hospital
Canning Road
Hastings 
New Zealand 4120</address>
      <phone>+64-27-2340063</phone>
      <fax />
      <email>craig.ellis@hawkesbaydhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Craig Ellis</name>
      <address>c/o Emergency Department
Hawkes Bay Regional Hospital
Canning Road
Hastings
New Zealand 4120</address>
      <phone>+64-27-2340063</phone>
      <fax />
      <email>craig.ellis@hawkesbaydhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>